Literature DB >> 24396658

Indications for fine needle aspiration in thyroid nodules.

Jin Young Kwak1.   

Abstract

Thyroid nodules are a common clinical problem with the widespread use of ultrasonography. Fine needle aspiration (FNA) is the mainstay for diagnosing a thyroid malignancy. There have been several guidelines on when to perform FNA in thyroid nodules. This review is based on several published recommendations and helps physicians easily understand the factors favoring FNA.

Entities:  

Keywords:  Biopsy, fine-needle; Indications; Thyroid; Thyroid malignancy; Thyroid nodule; Ultrasonography

Year:  2013        PMID: 24396658      PMCID: PMC3811719          DOI: 10.3803/EnM.2013.28.2.81

Source DB:  PubMed          Journal:  Endocrinol Metab (Seoul)        ISSN: 2093-596X


INTRODUCTION

With the increase in worldwide use of neck ultrasonography (US), the detection of thyroid nodules has rapidly increased to up to 67% of patients who undergo neck US [1]. Among them, only 4% to 7% of patients have palpable nodules on physical examination [2]. In South Korea, the yearly incidence has rapidly increased from 6.3 per 100,000 in 1999 to 47.5 per 100,000 in 2009 [3]. Fine needle aspiration (FNA) is the standard tool for detecting thyroid cancer and has led to a decrease in the number of thyroid surgeries and an increase in cancer detected during thyroid surgery [4-6]. The overall incidence of thyroid cancer is about 9.2% to 13% in patients with thyroid nodules who undergo FNA [7-9]. Also, the high detection rate of US makes FNA for all US-detected nodules impractical, if not impossible. Therefore, deciding which nodules should be biopsied is an important medical issue to ensure that no clinically significant thyroid cancers are missed. There are several guidelines for the indications of FNA in thyroid nodules [10-14]. This work demonstrates these guidelines and compares their merits.

CONSIDERATION FACTORS TO PERFORM FNAs

Size

Thyroid nodule size itself is not a predictive factor of malignancy [7,9-11]. Nevertheless, most guidelines recommend FNA for nodules larger than 10 mm [11,13,15], unless patients have high risk factors [15] or suspicious US features [13]. High risk factors include a history of thyroid cancer in one or more first-degree relatives, a history of exposure to external beam radiation or ionizing radiation in childhood or adolescence, prior hemithyroidectomy with discovery of thyroid cancer, fluorodeoxyglucose (18F) avidity on positron emission tomography scanning, multiple endocrine neoplasia (MEN) 2/familial medullary thyroid cancer-associated RET proto-oncogene mutation, or calcitonin levels >100 pg/mL [15]. Based on the revised American Thyroid Association (ATA) guidelines, FNA is recommended in thyroid nodules larger than 5 mm with suspicious US features in high risk patients. This guideline does not recommend FNA in thyroid nodules smaller than 5 mm. The size criterion for FNA is slightly different between the ATA and the American Association of Clinical Endocrinologists/Associazione Medici Endocrinologi (AACE/AME) guidelines. The AACE/AME guidelines suggests that FNA be performed regardless of lesion size when patients have a history of neck irradiation, a family history of medullary thyroid cancer or MEN2, extracapsular growth, or metastatic cervical lymph nodes [13]. The Korean Society of Thyroid Radiology (KSThR) has an even more strict size criteria [14]. They recommend FNA in thyroid nodules larger than 5 mm with suspicious US features, even when a patient does not have high risk factors. They also recommend selective FNA in thyroid nodules smaller than 5 mm according to risk factors and according to the performing radiologist's experience. This diversity in size criteria stems from the uncertainty regarding the clinical meaning of early diagnosis for tiny thyroid cancers in patients at low risk. The rationale behind the recommendations for FNA in larger nodules is based on a high rate of false positives and nondiagnostic cytology in thyroid nodules smaller than 5 mm [16,17].

Number of nodules

Traditionally, single nodules are considered to be at more risk for malignancy than multiple nodules. However, patients with multiple thyroid nodules do not have a decreased likelihood of thyroid cancer when compared to patients with solitary nodules [7,18]. The incidence of thyroid cancer in patients with multiple nodules is the same as that in patients with a solitary nodule, although the cancer rate per nodule decreases in patients with multiple nodules [19]. Thus, an FNA operator should focus on the US features of each individual nodule to decide whether or not to perform FNA.

Interval growth

Nodule growth is defined when a nodule shows more than a 50% increase in volume or a 20% increase in at least two nodule dimensions with a minimal increase of 2 mm in solid or in the solid portion of mixed nodules [15] in order to minimize interobserver bias of each measurement (Fig. 1) [20]. Although the growth itself is not a pathognomonic feature of malignancy [21] and the risk of malignancy is very low in a thyroid nodule with benign cytology [13], repeated FNA is usually indicated in nodules that increase in size [14,15].
Fig. 1

Ultrasonography (US) of growing benign mass in a 40-year-old woman who underwent fine needle aspiration twice. (A) Transverse and (B) longitudinal US images demonstrate a 0.7-cm-sized isoechoic nodule with the cystic portion of the posterior portion of the nodule in the right thyroid gland. (C, D) After 4 years, the nodule was enlarged. The cytology was benign, twice.

US features

Internal content of nodules

Depending on the components of the internal part of the thyroid nodule, nodules can be classified into cystic, mixed (both solid and cystic components), and solid nodules [22-24]. In cases where microcysts are aggregated in mixed nodules, the nodule is further defined as spongiform [25]. An anechoic cyst is definitely benign and can contain hyperechoic spots with comet tail artifacts. The comet tail artifacts are related to microcrystals inside colloid cysts which should be differentiated from the microcalcifications of malignant nodules. Solidity itself is not considered a suspicious US feature. However, several guidelines recommend FNA in solid nodules larger than 10 mm and mixed echoic nodules larger than 15 mm with some variation in the defining size depending on the guidelines used [11,15].

Echogenicity

Traditionally, hypoechogenicity is a well-known US feature related to malignancy, and most thyroid carcinomas are hypoechoic compared with surrounding thyroid parenchyma [10,26,27]. Hypoechogenicity is a very sensitive sign of malignancy but is less specific than other features. Marked hypoechogenicity is defined as decreased echogenicity less than that of the adjacent strap muscle [10] and is a specific sign of thyroid cancer. The ATA and AACE/AME consider hypoechogenicity as a suspicious US feature [13,15]. In comparison, the KSThR considers marked hypoechogenicity as a suspicious US feature [14].

Calcification

Microcalcification is a very specific US finding that suggests thyroid malignancy [11,13,15,22,24]. It is defined as a prominent echogenic focus with or without posterior shadowing. Unlike other reports [11,13,15,22,24], the KSThR considers both microcalcification and macrocalcification as suspicious US features [14].

Margin

The analysis of nodule margins is very subjective, resulting in very low interobserver agreement [28-32]. Microlobulated, irregular, infiltrative, or speculated margins have been considered as suspicious US features.

Shape

A taller than wide shape was first described by Kim et al. [10], after which it has been considered a suspicious US feature [13-15]. Although the ATA guidelines suggests that a taller than wide shape on transverse view alone is a suspicious US feature, a recent study demonstrates that a taller than wide shape in either the transverse or longitudinal plane can be accurate and sensitive for predicting thyroid malignancy [33].

Vascularity

Intranodular and chaotic vascularity have been considered as suspicious US features [13,15]. Recently, Moon et al. [34] published a study with color Doppler US performed on 1,083 nodules and showed that there was actually more blood flow distribution in benign nodules than in malignant nodules, and that vascularity was not helpful in differentiating benign and malignant nodules. The KSThR does not consider vascular pattern as a suspicious US feature [14].

Combinations of several suspicious US features

All of the US features explained thus far cannot alone diagnose thyroid nodules. The risk of malignancy increases as the number of suspicious US features increases (Fig. 2) [13,24].
Fig. 2

Ultrasonography (US) of papillary thyroid cancer in a 60-year-old woman who underwent surgery. (A) Transverse and (B) longitudinal US images demonstrate a 1-cm-sized hypoechoic taller than wide nodule with an irregular margin and internal microcalcifications in the right thyroid gland.

CONCLUSIONS

Current guidelines vary on how to differentiate thyroid nodules into benign or malignant nodules through US. Reported guidelines show substantial overlap in what defines benign and malignant nodules, and what might be considered benign by one recommendation might be considered malignant by another. Another issue is that US assessment is subjective and operator-dependent. Therefore, US performers should continuously compare their readings with confirmed diagnostic results to maintain and improve proficient diagnostic abilities.
  34 in total

1.  New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid.

Authors:  Eun-Kyung Kim; Cheong Soo Park; Woung Youn Chung; Ki Keun Oh; Dong Ik Kim; Jong Tae Lee; Hyung Sik Yoo
Journal:  AJR Am J Roentgenol       Date:  2002-03       Impact factor: 3.959

2.  Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement.

Authors:  Mary C Frates; Carol B Benson; J William Charboneau; Edmund S Cibas; Orlo H Clark; Beverly G Coleman; John J Cronan; Peter M Doubilet; Douglas B Evans; John R Goellner; Ian D Hay; Barbara S Hertzberg; Charles M Intenzo; R Brooke Jeffrey; Jill E Langer; P Reed Larsen; Susan J Mandel; William D Middleton; Carl C Reading; Steven I Sherman; Franklin N Tessler
Journal:  Radiology       Date:  2005-12       Impact factor: 11.105

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  A taller-than-wide shape in thyroid nodules in transverse and longitudinal ultrasonographic planes and the prediction of malignancy.

Authors:  Hee Jung Moon; Jin Young Kwak; Eun-Kyung Kim; Min Jung Kim
Journal:  Thyroid       Date:  2011-08-30       Impact factor: 6.568

5.  Interobserver variation for ultrasound determination of thyroid nodule volumes.

Authors:  V F H Brauer; P Eder; K Miehle; T D Wiesner; H Hasenclever; R Paschke
Journal:  Thyroid       Date:  2005-10       Impact factor: 6.568

6.  American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules.

Authors:  Hossein Gharib; Enrico Papini; Roberto Valcavi; H Jack Baskin; Anna Crescenzi; Massimo E Dottorini; Daniel S Duick; Rinaldo Guglielmi; Carlos Robert Hamilton; Martha A Zeiger; Michele Zini
Journal:  Endocr Pract       Date:  2006 Jan-Feb       Impact factor: 3.443

7.  Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features.

Authors:  Kyung-Eun Kim; Eun-Kyung Kim; Jung Hyun Yoon; Kyung Hwa Han; Hee Jung Moon; Jin Young Kwak
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

8.  Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings.

Authors:  Il Seong Nam-Goong; Ha Young Kim; Gyungyub Gong; Ho Kyu Lee; Suck Joon Hong; Won Bae Kim; Young Kee Shong
Journal:  Clin Endocrinol (Oxf)       Date:  2004-01       Impact factor: 3.478

9.  Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care.

Authors:  B Hamberger; H Gharib; L J Melton; J R Goellner; A R Zinsmeister
Journal:  Am J Med       Date:  1982-09       Impact factor: 4.965

Review 10.  Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations.

Authors:  Won-Jin Moon; Jung Hwan Baek; So Lyung Jung; Dong Wook Kim; Eun Kyung Kim; Ji Young Kim; Jin Young Kwak; Jeong Hyun Lee; Joon Hyung Lee; Young Hen Lee; Dong Gyu Na; Jeong Seon Park; Sun Won Park
Journal:  Korean J Radiol       Date:  2011-01-03       Impact factor: 3.500

View more
  13 in total

1.  Usefulness of NRAS codon 61 mutation analysis and core needle biopsy for the diagnosis of thyroid nodules previously diagnosed as atypia of undetermined significance.

Authors:  Eun Kyung Jang; Won Gu Kim; Eui Young Kim; Hyemi Kwon; Yun Mi Choi; Min Ji Jeon; Jung Hwan Baek; Jeong Hyun Lee; Tae Yong Kim; Young Kee Shong; Jene Choi; Dong Eun Song; Won Bae Kim
Journal:  Endocrine       Date:  2015-11-07       Impact factor: 3.633

2.  Solitary skin metastasis of papillary thyroid carcinoma.

Authors:  Hyemi Kwon; Hyojung Kim; Sojung Park; Dong Eun Song; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Won Bae Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2014-05-27

3.  Necessity of Fine-Needle Aspiration in Probably Benign Sonographic Appearance of Thyroid Nodules.

Authors:  Aida Sharifi Haddad; Behzad Aminzadeh; Seyed Ali Alamdaran; Shokoufeh Bonakdaran; Amirhosein Jafarian; Samira Rahemi; Negar Morovatdar; Ramesh Giti
Journal:  Iran J Otorhinolaryngol       Date:  2021-07

4.  NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma.

Authors:  Eun Kyung Jang; Dong Eun Song; So Young Sim; Hyemi Kwon; Yun Mi Choi; Min Ji Jeon; Ji Min Han; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Won Bae Kim
Journal:  Thyroid       Date:  2014-06-11       Impact factor: 6.568

Review 5.  Occult thyroid carcinoma: a rare case report and review of literature.

Authors:  Haiguang Liu; Lin Lv; Kai Yang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

6.  Thyroid nodule ultrasound: technical advances and future horizons.

Authors:  Andrew S McQueen; Kunwar S S Bhatia
Journal:  Insights Imaging       Date:  2015-03-05

7.  Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III.

Authors:  Magdalena Mileva; Bojana Stoilovska; Anamarija Jovanovska; Ana Ugrinska; Gordana Petrushevska; Slavica Kostadinova-Kunovska; Daniela Miladinova; Venjamin Majstorov
Journal:  Radiol Oncol       Date:  2018-09-27       Impact factor: 2.991

8.  Brief review of articles in 'endocrinology and metabolism' in 2013.

Authors:  Won-Young Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2014-09

9.  Correlation of Thyroid Imaging Reporting and Data System [TI-RADS] and fine needle aspiration: experience in 1,000 nodules.

Authors:  Antonio Rahal; Priscila Mina Falsarella; Rafael Dahmer Rocha; João Paulo Bacellar Costa Lima; Matheus Jorge Iani; Fábio Augusto Cardillo Vieira; Marcos Roberto Gomes de Queiroz; Jairo Tabacow Hidal; Miguel José Francisco; Rodrigo Gobbo Garcia; Marcelo Buarque de Gusmão Funari
Journal:  Einstein (Sao Paulo)       Date:  2016 Apr-Jun

10.  Impact of Reclassification on Thyroid Nodules with Architectural Atypia: From Non-Invasive Encapsulated Follicular Variant Papillary Thyroid Carcinomas to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.

Authors:  Min Ji Jeon; Dong Eun Song; Chan Kwon Jung; Won Gu Kim; Hyemi Kwon; Yu-Mi Lee; Tae-Yon Sung; Jong Ho Yoon; Ki-Wook Chung; Suck Joon Hong; Jung Hwan Baek; Jeong Hyun Lee; Tae Yong Kim; Young Kee Shong; Won Bae Kim
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.